Transaction · 0001857177-26-000008

Moat Ross

Moat Ross, COO, reported a transaction classified as grant at Kiniksa Pharmaceuticals International, plc involving 9250.000000 shares for an estimated $0.00. Reported holdings after the transaction were 9250.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACOO
KNSAKiniksa Pharmaceuticals International, plc
Trade date
Sep 01, 2026
Filing date
Sep 03, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded9.25k$0.00 per share
Holdings after9.25kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

KNSA price since this filing

Daily closing prices, with the filing date and available return windows
KNSA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -7.6%1w ago -0.8%1d ago -2.3%
Returns since7d -5.0%30d -5.8%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001857177-26-000008
Restricted Share Unit
Transaction date
Sep 01, 2026
Filed Sep 03, 2026, 08:41 PM · 2d delay
Shares
9,250 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
9,250 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Increase
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF OPERATING OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

  2. F2

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.

  3. F3

    The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting comme…

  4. F4

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.

  5. F5

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.

  6. F6

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

  7. F7

    The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

Original filing · 0001857177-26-000008
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

KNSA